Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

NCT04631731 is registered in ClinicalTrials.gov with Western Sydney Local Health District as lead sponsor.

NCT NCT04631731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04631731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
Lead sponsor
Western Sydney Local Health District
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 15, 2020
Completion date
December 10, 2025
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, gastric cancer, hepatocellular carcinoma, lung cancer, nonsmall cell, melanoma, mesothelioma, renal cell carcinoma